| Name | Title | Contact Details |
|---|
Patheous Health is a company that specializes in dysphagia healthcare and swallowing impairment conditions. They offer an Integrated Dysphagia Healthcare (iDH) platform and provide service solutions for both MBS and FEES studies.
Center for Industrial Training is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Center for Industrial Training is based in Mechanicsburg, PA. You can find more information on Center for Industrial Training at www.cparc.org
Eureka93 is one of the largest hemp cultivation and CBD extraction operations in North America. We are dedicated to producing the highest quality CBD products for our customers.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
First MCO is unique in the worker`s compensation industry in that it develops networks of specialists where the employers have the ability to direct care to them. With a rich 36-year company history, First MCO has grown into national experts in driving care for private and public sectors. The company works with insurance companies, self-insurers, third party administrators and insurance funds to provide comprehensive medical management and cost containment services for workers` compensation in New Jersey, Nevada, Missouri, Pennsylvania, Virginia, and Connecticut. The skilled medical team and professional staff at First MCO pride themselves on individualized customer service and convenient managed care solutions to get people back to work.